Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INDV | 425 | bullish | 8/10 | Indivior reported record Q2 2026 results with total net revenue of $343M (up 14% YoY), record SUBLOCADE net revenue of $ | Aug 3, 2026 |
| INDV | 8-K | bullish | 8/10 | Indivior reported record Q2 2026 results with total net revenue of $343M (+14% YoY), record SUBLOCADE net revenue of $25 | Aug 3, 2026 |
| SUPN | 8-K | mixed | 7/10 | Supernus Pharmaceuticals reported Q2 2026 total revenues of $219.1M (+32% YoY), beating consensus of $205.4M, but GAAP n | Aug 3, 2026 |
| BNTX | 6-K | neutral | 3/10 | BioNTech announced the appointment of Guido Oelkers as CEO, effective by February 1, 2027, succeeding co-founder Prof. U | Aug 3, 2026 |
| BTAI | 8-K | bearish | 7/10 | BioXcel Therapeutics entered its Eleventh Amendment to the Oaktree credit agreement, deferring a $9.0M payment to August | Aug 3, 2026 |
| GNPX | 8-K | neutral | 4/10 | Genprex announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in | Aug 3, 2026 |
| CGEN | 6-K | neutral | 4/10 | Compugen reported Q2 2026 results broadly in line with expectations. Revenue rose 35% YoY to $4.8M (H1) driven by Gilead | Aug 3, 2026 |
| SPTX | 8-K | neutral | 5/10 | Seaport Therapeutics reported Q2 2026 results: net loss of $62.6M ($1.78/share) versus consensus of -$0.71, a miss drive | Aug 3, 2026 |
| CANF | 6-K | bullish | 5/10 | Can-Fite BioPharma announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, an u | Aug 3, 2026 |
| TNXP | 8-K | bullish | 6/10 | Tonix announced FDA alignment on the adaptive Phase 2 field study design for TNX-4800, a long-acting monoclonal antibody | Aug 3, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma appointed Dr. Faical Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, crea | Aug 3, 2026 |
| RCKT | 8-K | bullish | 6/10 | Rocket Pharmaceuticals announced a positive clinical safety update from the first three patients treated under the modif | Aug 3, 2026 |
| CGEN | 6-K | neutral | 2/10 | Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The meeting will cover the ele | Aug 3, 2026 |
| RADX | 6-K | bearish | 6/10 | Radiopharm Theranostics filed a 6-K to report the quotation of 408,839,531 ordinary shares on the ASX at AUD 0.015 per s | Aug 3, 2026 |
| ANL | 6-K | bullish | 6/10 | Adlai Nortye announced CTN submission and HREC approval to begin a Phase I trial of AN4035, a first-in-class pan-RAS(ON) | Aug 3, 2026 |
| AUTL | 8-K | bullish | 7/10 | Autolus Therapeutics raised FY2026 AUCATZYL net product revenue guidance to $140M-$150M (from $120M-$135M) and reported | Aug 3, 2026 |
| CMND | 6-K | mixed | 6/10 | Clearmind Medicine (CMND) announced a non-binding LOI to acquire a 51% majority stake in an EV wireless charging solutio | Aug 3, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex Life Sciences announced a board refresh plan, nominating two new independent directors and responding to an activ | Aug 3, 2026 |
| INDV | 425, 8-K | bullish | 8/10 | Indivior reported record Q2 2026 results with total net revenue of $343M (up 14% YoY), record SUBLOCADE revenue of $253M | Aug 3, 2026 |
| SUPN | 8-K | bullish | 7/10 | Supernus Pharmaceuticals and Indivior announced a merger of equals in a 100% tax-free stock-for-stock transaction. Super | Aug 3, 2026 |
| SUPN | DEFA14A, 425 | bullish | 8/10 | Supernus Pharmaceuticals has announced a definitive merger of equals with Indivior Pharmaceuticals in a 100% tax-free st | Aug 3, 2026 |
| LNTH | DEFA14A, 8-K | bullish | 7/10 | Lantheus (LNTH) has entered into a definitive merger agreement with Curium US Holdings LLC, a private equity-backed radi | Aug 3, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a routine 6-K notification of admission of 8,855 ordinary shares under its employee share schemes, iss | Aug 3, 2026 |
| SBFM | 8-K | neutral | 3/10 | Sunshine Biopharma disclosed that recent sales under its at-the-market (ATM) offering triggered an automatic reduction i | Aug 3, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine appointed Michael J. Grissinger to its Board of Directors, expanding the board to five members. Grissinger brin | Aug 3, 2026 |
| MBRX | 424B5 | bearish | 8/10 | Moleculin Biotech is conducting a deeply dilutive 'reasonable best efforts' public offering at $0.75 per share (66% disc | Aug 3, 2026 |
| TOI | 8-K | neutral | 2/10 | Oncology Institute, Inc. is rebranding as Starling Oncology, Inc. effective July 28, 2026, with its Nasdaq ticker changi | Aug 3, 2026 |
| DSGN | 8-K | mixed | 5/10 | Design Therapeutics reported Q2 2026 financial results with a net loss of $20.2M ($0.32 per share), beating consensus of | Aug 3, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced that the final subject received their last dose in the Phase 2 DURIPANC trial of Ampligen for m | Aug 3, 2026 |
| PTHS | PRESS-RELEASE | neutral | 1/10 | Pelthos Therapeutics, Inc. announced it will report its Q2 2026 results on August 13, 2026. | Aug 3, 2026 |